Trial Profile

Pharmacokinetic study of new formulation of dronabinol in patients with obstructive sleep apnoea

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dronabinol (Primary)
Indications Sleep apnoea syndrome
Focus Pharmacokinetics
Sponsors RespireRx Pharmaceuticals

Most Recent Events

10 Aug 2020 Patient gender and drug route assumed.
10 Aug 2020 New trial record
03 Aug 2020 According to a RespireRx Pharmaceuticals media release, pending the completion of a new formulation of dronabinol and an intended pre-IND meeting with the FDA, the company believes that it will be able to commence a pharmacokinetic study for the new formulation for the treatment of OSA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com